Published in Mol Oncol on October 16, 2010
New Individualized Therapy Trial for Metastatic Colorectal Cancer (NITMEC) | NCT00867334
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell (2013) 1.75
Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society. Mol Cell Proteomics (2014) 1.11
One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One (2011) 1.03
MALDI imaging mass spectrometry--painting molecular pictures. Mol Oncol (2010) 0.96
Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress. Exp Cell Res (2013) 0.93
Laser capture microdissection for protein and NanoString RNA analysis. Methods Mol Biol (2013) 0.90
Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples. Biotechniques (2012) 0.89
Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. Clin Cancer Res (2013) 0.88
Reverse phase protein arrays: mapping the path towards personalized medicine. Mol Diagn Ther (2014) 0.85
Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics. J Transl Med (2015) 0.85
Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ (2013) 0.85
Is phosphoproteomics ready for clinical research? Clin Chim Acta (2012) 0.81
Analytical challenges translating mass spectrometry-based phosphoproteomics from discovery to clinical applications. Electrophoresis (2014) 0.81
Functional protein microarray as molecular decathlete: a versatile player in clinical proteomics. Proteomics Clin Appl (2012) 0.81
Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling. Front Physiol (2012) 0.80
A framework for personalized medicine: prediction of drug sensitivity in cancer by proteomic profiling. Proteome Sci (2012) 0.79
Levels of soluble E-cadherin in breast, gastric, and colorectal cancers. Biomed Res Int (2014) 0.78
Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases. J Transl Med (2015) 0.78
Quantitative phenotypic and pathway profiling guides rational drug combination strategies. Front Pharmacol (2014) 0.78
Host response during Yersinia pestis infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways. Front Microbiol (2015) 0.78
Immunocapture strategies in translational proteomics. Expert Rev Proteomics (2015) 0.77
Reverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use. Microarrays (Basel) (2015) 0.76
Integration of proteomics into systems biology of cancer. Wiley Interdiscip Rev Syst Biol Med (2012) 0.76
Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis. J Transl Med (2017) 0.75
The current state of the art of quantitative phosphoproteomics and its applications to diabetes research. Expert Rev Proteomics (2016) 0.75
Semi-quantitative measurement of specific proteins in human cumulus cells using reverse phase protein array. Reprod Biol Endocrinol (2013) 0.75
Reverse phase protein arrays in signaling pathways: a data integration perspective. Drug Des Devel Ther (2015) 0.75
High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancer. J Pathol Clin Res (2014) 0.75
Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma. Am J Transl Res (2014) 0.75
[Personalized oncology]. Radiologe (2017) 0.75
Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Front Pharmacol (2017) 0.75
Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 88.48
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Laser capture microdissection. Science (1996) 12.21
Signaling--2000 and beyond. Cell (2000) 11.78
Printing proteins as microarrays for high-throughput function determination. Science (2000) 10.77
The microenvironment of the tumour-host interface. Nature (2001) 9.17
Involvement of the bcl-2 gene in human follicular lymphoma. Science (1985) 8.19
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol (2002) 7.17
The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science (1985) 6.63
Formaldehyde fixation. J Histochem Cytochem (1985) 5.89
A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature (2005) 5.75
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
A highly sensitive silver stain for detecting proteins and peptides in polyacrylamide gels. Anal Biochem (1979) 4.77
Multiple myeloma. Lancet (2009) 4.60
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 4.40
From signatures to models: understanding cancer using microarrays. Nat Genet (2005) 4.29
A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat Methods (2009) 4.23
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol (2001) 3.58
Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Methods (1989) 3.39
Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol (1997) 3.35
Clinical proteomics: written in blood. Nature (2003) 2.81
Protein chip technology. Curr Opin Chem Biol (2003) 2.80
Molecular profiling of human cancer. Nat Rev Genet (2000) 2.64
Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem (2006) 2.55
Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med (2006) 2.53
Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol (2002) 2.50
On the meaning of "sensitivity". Clin Chem (1997) 2.43
Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics (2008) 2.43
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques (2004) 2.36
Antibodypedia, a portal for sharing antibody and antigen validation data. Mol Cell Proteomics (2008) 2.34
Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 2.32
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol (2006) 2.24
Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther (1999) 2.18
Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem (1996) 2.11
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res (2009) 2.10
Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A (2010) 2.10
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res (2007) 2.07
Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc (2008) 1.99
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther (2008) 1.90
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics (2008) 1.88
High-throughput phosphotyrosine profiling using SH2 domains. Mol Cell (2007) 1.72
Multi-analyte immunoassay. J Pharm Biomed Anal (1989) 1.70
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
Protein microarray technology. Trends Biotechnol (2002) 1.68
Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics (2003) 1.68
Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers (2001) 1.67
Profiling protein thiol oxidation in tumor cells using sulfenic acid-specific antibodies. Proc Natl Acad Sci U S A (2009) 1.61
Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol (2007) 1.60
Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics (2004) 1.57
Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J Immunol Methods (1991) 1.54
Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics (2002) 1.53
Kinetic studies of formaldehyde binding in tissue. Biotech Histochem (1994) 1.50
State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling. Nat Methods (2006) 1.50
The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src. EMBO J (1997) 1.47
High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem (2005) 1.47
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics (2003) 1.44
Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem (2005) 1.43
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res (2009) 1.43
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 1.40
Predicting cancer drug response by proteomic profiling. Clin Cancer Res (2006) 1.39
Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat Struct Biol (2000) 1.36
Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One (2010) 1.35
Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol (2009) 1.33
Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res (2005) 1.31
Clinical proteomics: personalized molecular medicine. JAMA (2001) 1.30
Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res (2010) 1.30
Robust-linear-model normalization to reduce technical variability in functional protein microarrays. J Proteome Res (2009) 1.29
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther (2007) 1.29
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res (2010) 1.29
Antibody arrays: technical considerations and clinical applications in cancer. Clin Chem (2006) 1.26
Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci U S A (2004) 1.25
Infrared-based protein detection arrays for quantitative proteomics. Proteomics (2007) 1.25
Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One (2009) 1.23
Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J (2007) 1.22
Combinatorial RNAi for quantitative protein network analysis. Proc Natl Acad Sci U S A (2007) 1.21
A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J Pathol (1997) 1.18
Optimal design of microarray immunoassays to compensate for kinetic limitations: theory and experiment. Mol Cell Proteomics (2006) 1.18
Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest (2004) 1.18
Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain. J Neurochem (2005) 1.17
Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol (2010) 1.17
A high confidence, manually validated human blood plasma protein reference set. BMC Med Genomics (2008) 1.16
Development of a prostate cDNA microarray and statistical gene expression analysis package. Mol Carcinog (2000) 1.16
Evaluation of surface chemistries for antibody microarrays. Anal Biochem (2007) 1.15
Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocrinol Metab (2002) 1.15
Personalized medicine. Curr Opin Mol Ther (2002) 1.13
Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology (2003) 1.13
Multianalyte microspot immunoassay--microanalytical "compact disk" of the future. Clin Chem (1991) 1.12
Selectivity and promiscuity in the interaction network mediated by protein recognition modules. FEBS Lett (2004) 1.12
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Laser-capture microdissection. Nat Protoc (2006) 3.80
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Proteomic applications for the early detection of cancer. Nat Rev Cancer (2003) 3.61
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 2.32
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
Breast cancer stem cells: a new target for therapy. Oncology (Williston Park) (2011) 2.09
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res (2007) 2.07
An investigation into the human serum "interactome". Electrophoresis (2004) 1.93
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics (2008) 1.88
A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem (2007) 1.87
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics (2002) 1.85
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol (2004) 1.81
The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer (2006) 1.79
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res (2012) 1.74
Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res (2003) 1.73
Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res (2010) 1.73
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov (2007) 1.73
Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem (2003) 1.69
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics (2003) 1.66
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett (2007) 1.58
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
Anoikis: cancer and the homeless cell. Nature (2004) 1.54
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res (2002) 1.53
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
Counterpoint: The vision for a new diagnostic paradigm. Clin Chem (2003) 1.50
Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol (2002) 1.48
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics (2003) 1.44
Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem (2005) 1.43
Laser capture microdissection technology. Expert Rev Mol Diagn (2007) 1.43
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic (2002) 1.42
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 1.40
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer (2007) 1.36
Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One (2010) 1.35
Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics (2003) 1.33
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics (2002) 1.31
Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res (2005) 1.31
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem (2008) 1.31
Cancer: Out of air is not out of action. Nature (2003) 1.30
Ovarian cancer detection by logical analysis of proteomic data. Proteomics (2004) 1.28
Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J Biol Chem (2006) 1.28
Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia (2002) 1.26
Biomarker amplification by serum carrier protein binding. Dis Markers (2004) 1.26
An initial characterization of the serum phosphoproteome. J Proteome Res (2009) 1.26
Physiological mechanisms of tumor-cell invasion and migration. Physiology (Bethesda) (2005) 1.25
Clinical proteomics and biomarker discovery. Ann N Y Acad Sci (2004) 1.24
Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One (2009) 1.23
Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol (2006) 1.23
Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol (2006) 1.23
Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol (2004) 1.20
Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest (2004) 1.18
Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J Proteome Res (2004) 1.17
Cancer's deadly signature. Nat Genet (2003) 1.16
Expression microdissection: operator-independent retrieval of cells for molecular profiling. Diagn Mol Pathol (2004) 1.16
A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res (2004) 1.16
Laser capture microdissection. Methods Mol Biol (2006) 1.12
Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc (2011) 1.11
Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol (2007) 1.10
Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest (2010) 1.09
Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn (2007) 1.09
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat (2014) 1.08
CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics (2005) 1.08
The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer (2007) 1.08
Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl (2009) 1.08
Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays. Bioconjug Chem (2005) 1.07
Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles. Nano Res (2008) 1.07
Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res (2011) 1.07
Pathology of the future: molecular profiling for targeted therapy. Cancer Invest (2005) 1.06
Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype. Proc Natl Acad Sci U S A (2003) 1.06
Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics (2004) 1.05